TRAP
MCID: TWN015
MIFTS: 31

Twin-Reversed Arterial Perfusion Sequence (TRAP)

Categories: Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Twin-Reversed Arterial Perfusion Sequence

MalaCards integrated aliases for Twin-Reversed Arterial Perfusion Sequence:

Name: Twin-Reversed Arterial Perfusion Sequence 58
Trap 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Orphanet 58 ORPHA617297

Summaries for Twin-Reversed Arterial Perfusion Sequence

MalaCards based summary: Twin-Reversed Arterial Perfusion Sequence, also known as trap, is related to endocarditis and neural tube defects. The drugs Certoparin and Heparin, bovine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, eye and bone marrow.

Related Diseases for Twin-Reversed Arterial Perfusion Sequence

Diseases related to Twin-Reversed Arterial Perfusion Sequence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1057)
# Related Disease Score Top Affiliating Genes
1 endocarditis 11.0
2 neural tube defects 11.0
3 myeloperoxidase deficiency 11.0
4 hidradenitis suppurativa 10.9
5 immune system disease 10.9
6 polyhydramnios 10.7
7 preterm premature rupture of the membranes 10.6
8 twin-to-twin transfusion syndrome 10.5
9 acardia 10.5
10 malaria 10.5
11 dengue disease 10.4
12 common cold 10.4
13 selective intrauterine growth restriction 10.4
14 charge syndrome 10.4
15 hair whorl 10.3
16 hydrops fetalis, nonimmune 10.3
17 disseminated intravascular coagulation 10.3
18 congestive heart failure 10.3
19 autoimmune disease 10.3
20 global developmental delay, lung cysts, overgrowth, and wilms tumor 10.3
21 vasculitis 10.3
22 macular degeneration, age-related, 1 10.3
23 adult respiratory distress syndrome 10.3
24 vaccinia 10.2
25 parkinson disease, late-onset 10.2
26 lung cancer 10.2
27 microvascular complications of diabetes 5 10.2
28 chikungunya 10.2
29 chronic bilirubin encephalopathy 10.2
30 systemic lupus erythematosus 10.2
31 west nile virus 10.2
32 rapidly involuting congenital hemangioma 10.2
33 hydrocephalus, congenital, 1 10.2
34 spastic ataxia, charlevoix-saguenay type 10.2
35 patent ductus arteriosus 1 10.2
36 leukemia, acute lymphoblastic 3 10.2
37 deficiency anemia 10.2
38 b-lymphoblastic leukemia/lymphoma 10.2
39 microcephaly 10.2
40 pericardial effusion 10.2
41 heart septal defect 10.2
42 atrial heart septal defect 10.2
43 teratoma 10.2
44 holoprosencephaly 10.2
45 hydranencephaly 10.2
46 polycythemia 10.2
47 phocomelia 10.2
48 interatrial communication 10.2
49 twin anemia-polycythemia sequence 10.2
50 gastric antral vascular ectasia 10.2

Graphical network of the top 20 diseases related to Twin-Reversed Arterial Perfusion Sequence:



Diseases related to Twin-Reversed Arterial Perfusion Sequence

Symptoms & Phenotypes for Twin-Reversed Arterial Perfusion Sequence

Drugs & Therapeutics for Twin-Reversed Arterial Perfusion Sequence

Drugs for Twin-Reversed Arterial Perfusion Sequence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Certoparin Approved, Investigational Phase 4
2
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
3
Reviparin Approved, Investigational Phase 4 9041-08-1
4
Aflibercept Approved Phase 4 862111-32-8 124490314
5
Verteporfin Approved, Investigational Phase 4 129497-78-5 5362420
6
Ranibizumab Approved Phase 4 347396-82-1
7
Rilonacept Approved, Investigational Phase 4 501081-76-1
8 Fibrinolytic Agents Phase 4
9 Anticoagulants Phase 4
10 Calcium heparin Phase 4
11 Heparin, Low-Molecular-Weight Phase 4
12 Angiogenesis Inhibitors Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Vaccines Phase 4
15 Pharmaceutical Solutions Phase 4
16 Immunologic Factors Phase 4
17
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
18
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
19
Pertuzumab Approved Phase 3 380610-27-5
20
Trastuzumab Approved, Investigational Phase 3 180288-69-1
21 Endothelial Growth Factors Phase 3
22 Mitogens Phase 3
23 Dermatologic Agents Phase 3
24 Photosensitizing Agents Phase 3
25 Albumin-Bound Paclitaxel Phase 3
26 Antimitotic Agents Phase 3
27 Tubulin Modulators Phase 3
28 Antineoplastic Agents, Immunological Phase 3
29
Iodine Approved, Investigational Phase 2 7553-56-2 807
30
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
31
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
32
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
33
Colchicine Approved Phase 2 64-86-8 2833 6167
34
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
35
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
36
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
37
Dantrolene Approved, Investigational Phase 1, Phase 2 7261-97-4 6914273
38
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
39
Pirfenidone Approved, Investigational Phase 1, Phase 2 53179-13-8 40632
40
Clemastine Approved, Investigational Phase 1, Phase 2 15686-51-8 26987
41
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
42
Metronidazole Approved Phase 1, Phase 2 443-48-1, 69198-10-3 4173
43
Artesunate Approved, Investigational Phase 1, Phase 2 88495-63-0 6917864 5464098
44
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
45
Zoledronic acid Approved Phase 2 118072-93-8 68740
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Cadexomer iodine Experimental Phase 2 94820-09-4
48
Ifetroban Investigational Phase 2 143443-90-7 3037233
49
Pyronaridine Investigational Phase 1, Phase 2 74847-35-1 5485198
50 Vitamins Phase 2

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy Unknown status NCT02621645 Phase 4
2 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
3 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
4 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
5 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
6 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01663103 Phase 4 Rilonacept;Placebo
7 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
8 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Active, not recruiting NCT01824537 Phase 4
9 A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
10 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration Completed NCT00509795 Phase 3
11 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
12 Trial to Reduce Alloimmunization to Platelets (TRAP) Completed NCT00000589 Phase 3
13 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
14 An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration Completed NCT00964795 Phase 3 Intravitreal Aflibercept Injection 2mg
15 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
16 An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema Completed NCT01512966 Phase 3
17 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema Completed NCT01363440 Phase 3 Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
18 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema Completed NCT01783886 Phase 3
19 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT01521559 Phase 3 Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
20 A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration Completed NCT01482910 Phase 3 Visudyne
21 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema Completed NCT01331681 Phase 3
22 The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study Recruiting NCT05188313 Phase 3 Trastuzumab;Pertuzumab;Paclitaxel;Carboplatin
23 A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT01652196 Phase 2 oxaliplatin;leucovorin;fluorouracil
24 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP Completed NCT00890760 Phase 1, Phase 2
25 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP Completed NCT01142765 Phase 1, Phase 2
26 A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children Completed NCT01635647 Phase 1, Phase 2
27 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
28 A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00462826 Phase 2
29 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Intravenous Boosting With Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP Completed NCT03707353 Phase 1, Phase 2
30 A Randomized, Single-Masked , Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects With Neovascular Age-related Macular Degeneration Completed NCT00527423 Phase 2 VEGF Trap Eye
31 A Nonrandomized, Open-label Study to Evaluate the Safety and Pharmacokinetics of Multiple Administration of RC28-E Injection (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration Completed NCT04270669 Phase 1, Phase 2
32 Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed NCT00436501 Phase 1, Phase 2 docetaxel
33 Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane Completed NCT00369655 Phase 2
34 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone. Completed NCT01883609 Phase 1, Phase 2
35 A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00396591 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
36 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone Completed NCT02252640 Phase 1, Phase 2
37 A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (DME) Completed NCT00789477 Phase 2 Intravitreal Aflibercept Injection
38 Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+Esophageal Carcinoma: the TRAP Study Completed NCT02120911 Phase 1, Phase 2 Pertuzumab, trastuzumab
39 A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma Completed NCT00450255 Phase 2
40 Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer Completed NCT00407654 Phase 2 aflibercept
41 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
42 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial Completed NCT00408668 Phase 1, Phase 2
43 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
44 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
45 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS Completed NCT01623557 Phase 1, Phase 2
46 Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF) Completed NCT00582907 Phase 2 Rilonacept;Placebo
47 Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis Completed NCT00094900 Phase 2 IL-1 Trap
48 Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection. Completed NCT01666925 Phase 2
49 X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept in Metastatic Colorectal Cancer Completed NCT01661972 Phase 1, Phase 2 Capecitabine and aflibercept
50 Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection Completed NCT01658696 Phase 2

Search NIH Clinical Center for Twin-Reversed Arterial Perfusion Sequence

Genetic Tests for Twin-Reversed Arterial Perfusion Sequence

Anatomical Context for Twin-Reversed Arterial Perfusion Sequence

Organs/tissues related to Twin-Reversed Arterial Perfusion Sequence:

MalaCards : Neutrophil, Eye, Bone Marrow, Bone, Endothelial, Liver, Lung

Publications for Twin-Reversed Arterial Perfusion Sequence

Articles related to Twin-Reversed Arterial Perfusion Sequence:

(show top 50) (show all 30116)
# Title Authors PMID Year
1
Effects of platelets activated by different agonists on fibrin formation and thrombin generation. 62
36325627 2023
2
Unravelling mechanisms of protein and lipid oxidation in mayonnaise at multiple length scales. 62
36303379 2023
3
Determination and speciation of methyl mercury and total mercury in fish tissue samples by gold-coated W-coil atom trap cold vapor atomic absorption spectrometry. 62
36099824 2023
4
Do neighbourhood traffic-related air pollution and socio-economic status moderate the associations of the neighbourhood physical environment with cognitive function? Findings from the AusDiab study. 62
36368384 2023
5
Long-term exposure to traffic-related air pollution and stroke: A systematic review and meta-analysis. 62
36446272 2023
6
Vanadium dioxide plates reduced graphene oxide as sulfur cathodes for efficient polysulfides trap in long-life lithium-sulfur batteries. 62
36152613 2023
7
Determining Protein-Protein Interaction with GFP-Trap Beads. 62
36107351 2023
8
Sensor-based evaluation of a Urine Trap toilet in a shared bathroom. 62
36202366 2023
9
Modulations in human neutrophil metabolome and S-glutathionylation of glycolytic pathway enzymes during the course of extracellular trap formation. 62
36265832 2023
10
Effects of long term diabetogenic high fat diet on bone in ovariectomized female rats. 62
35762155 2023
11
A rescue diet raises the plasma calcium concentration and ameliorates rheumatoid arthritis in mice: Role of CaSR-mediated inhibition of osteoclastogenesis. 62
36468692 2023
12
Parallel Pseudo-MRM on the "brick" miniature mass spectrometer for high throughput multi-target screening. 62
36041316 2023
13
Degradation of 3D-printed magnesium phosphate ceramics in vitro and a prognosis on their bone regeneration potential. 62
35574054 2023
14
Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases. 62
35951483 2023
15
Comparison of destructive and nondestructive DNA extraction methods for the metabarcoding of arthropod bulk samples. 62
35932285 2023
16
Exposure to a real traffic environment impairs brain cognition in aged mice. 62
36113572 2022
17
PKC-SWI6 signaling regulates asexual development, cell wall integrity, stress response, and lifestyle transition in the nematode-trapping fungus Arthrobotrys oligospora. 62
35829807 2022
18
Histochemical assessment on osteocytic osteolysis in lactating mice fed with a calcium-insufficient diet. 62
36152933 2022
19
Simultaneous detection of sibutramine and phenolphthalein in a diet jelly health food product that caused health problems. 62
36472786 2022
20
Association Between Physical Performance Tests and External Load During Scrimmages in Highly Trained Youth Ice Hockey Players. 62
36470253 2022
21
Eosinophils: Focus on DNA extracellular traps. 62
36379309 2022
22
Cell pairing for biological analysis in microfluidic devices. 62
36389274 2022
23
Characterization of radicals in polysorbate 80 using electron paramagnetic resonance (EPR) spectroscopy and spin trapping. 62
35795322 2022
24
Perspective of 2D Integrated Electronic Circuits: Scientific Pipe Dream or Disruptive Technology? 62
35318749 2022
25
Impact of melatonin on periodontal ligament fibroblasts during mechanical strain. 62
35396993 2022
26
Neutrophils Protect Against Staphylococcus aureus Endocarditis Progression Independent of Extracellular Trap Release. 62
36453281 2022
27
Performance of the cervical shortening for prediction of spontaneous preterm birth in uncomplicated twins. 62
34570673 2022
28
Placenta-specific protein 1 (PLAC1) expression is significantly down-regulated in preeclampsia via a hypoxia-mediated mechanism. 62
34565269 2022
29
FAEE exerts a protective effect against osteoporosis by regulating the MAPK signalling pathway. 62
35180021 2022
30
TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss. 62
35255774 2022
31
Traffic-related air pollution and genome-wide DNA methylation: A randomized, crossover trial. 62
35963411 2022
32
Na+ Selective Binding by Beauvericin and Its Mechanism Studied by Mass-Coupled Cold Ion Trap Infrared Spectroscopy. 62
36454047 2022
33
The Role of Bone Grafts in Preventing Medication-Related Osteonecrosis of the Jaw: Histomorphometric, Immunohistochemical, and Clinical Evaluation in Animal Model. 62
36387320 2022
34
An anticomplement homogeneous polysaccharide from Hedyotis diffusa attenuates lipopolysaccharide-induced acute lung injury and inhibits neutrophil extracellular trap formation. 62
36116199 2022
35
25-Hydroxycholesterol induces odontoclastic differentiation through RANK-RANKL upregulation and NF-κB activation in odontoblast-like MDPC-23 cells: An in vitro study. 62
36462163 2022
36
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. 62
35577211 2022
37
Epigallocatechin-3-gallate reduces neutrophil extracellular trap formation and tissue injury in severe acute pancreatitis. 62
35983712 2022
38
Microplastics: Is There Any Environmental Information about Insect Glue Trap Plastic (IGTP)? 62
36459460 2022
39
Citrinin stimulated heterophil extracellular trap formation in chickens. 62
36244215 2022
40
Timing of intra-fetal laser therapy for twin reversed arterial perfusion (TRAP) sequence: Retrospective series and systematic review and meta-analysis. 62
35435256 2022
41
Post-traumatic hamatolunate impingement: A diagnostic trap. Comment to: Hamatolunate impingement syndrome in golfers: Results of arthroscopic burring of the apex of the hamate (April 2022). 62
36113761 2022
42
Over 31% efficient indoor organic photovoltaics enabled by simultaneously reduced trap-assisted recombination and non-radiative recombination voltage loss. 62
36458496 2022
43
Genetic algorithm parallel optimization of a new high mass resolution planar electrostatic ion trap mass analyzer. 62
36413223 2022
44
Impurity profile and spectrum characteristics of the isomers in cefamandole nafate using high- performance liquid chromatography/high-performance size exclusion chromatography tandem ion trap/time-of-flight mass spectrometry. 62
36114650 2022
45
Differential metabolic profiles of ginsenosides in artificial gastric juice using ultra-high-pressure liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometry. 62
36044184 2022
46
Probing Intrinsic Defect-Induced Trap States and Hopping Transport in Two-Dimensional PdSe2 Semiconductor Devices. 62
36474350 2022
47
Crystalline Phases Regulate Electronic Trap States at Defective Surfaces of Lead Halide Perovskites. 62
36469403 2022
48
Verifying the efficiency of the Biogents Sentinel trap in the field and investigating microclimatic influences on responding Aedes aegypti behavior. 62
36314670 2022
49
[Remaining a physician-how to escape the commercialization trap]. 62
36471173 2022
50
Major anthocyanins in elderberry effectively trap methylglyoxal and reduce cytotoxicity of methylglyoxal in HepG2 cell line. 62
36281231 2022

Variations for Twin-Reversed Arterial Perfusion Sequence

Expression for Twin-Reversed Arterial Perfusion Sequence

Search GEO for disease gene expression data for Twin-Reversed Arterial Perfusion Sequence.

Pathways for Twin-Reversed Arterial Perfusion Sequence

GO Terms for Twin-Reversed Arterial Perfusion Sequence

Sources for Twin-Reversed Arterial Perfusion Sequence

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....